Your session is about to expire
← Back to Search
Gait Rehabilitation for Amputation (GEM Trial)
N/A
Recruiting
Led By Cory L. Christiansen, PhD
Research Sponsored by VA Office of Research and Development
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Able to ambulate in the community without assistive device
Step length asymmetry during walking (>1.0 asymmetry index.)
Must not have
Unstable heart condition including unstable angina, uncontrolled cardiac dysrhythmia, acute myocarditis, hypertension, and acute pericarditis
Active cancer treatment
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline (pre-intervention) to intervention end, persisting at 12 weeks after intervention end.
Awards & highlights
No Placebo-Only Group
Summary
This trial will evaluate two error-manipulation gait training programs to improve gait symmetry for Veterans with non-traumatic lower limb amputation, in hopes of reducing long-term disability.
Who is the study for?
This trial is for older Veterans with diabetes or peripheral artery disease who have had a non-traumatic amputation below the knee. They should be able to walk without help and have had their amputation between 6 months and 10 years ago. Those with traumatic or cancer-related amputations, unstable heart conditions, infections, or active cancer treatment cannot join.
What is being tested?
The study tests two gait training programs designed to improve walking symmetry in Veterans after lower limb loss: error-augmentation and error-correction training, plus supervised walking. It aims to see if these can reduce disability and improve skin health on the remaining limb.
What are the potential side effects?
While not explicitly listed, potential side effects may include muscle soreness, fatigue from exercise, skin irritation at the residual limb due to increased activity during gait training sessions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I can walk on my own without any help from devices.
Select...
My walking step lengths are uneven.
Select...
I have diabetes and/or peripheral artery disease.
Select...
I have had one lower leg amputated due to reasons other than injury.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have an unstable heart condition.
Select...
I am currently receiving treatment for cancer.
Select...
I currently have a serious infection.
Select...
I had an amputation due to injury or cancer.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline (pre-intervention) to intervention end, persisting at 12 weeks after intervention end.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline (pre-intervention) to intervention end, persisting at 12 weeks after intervention end.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Step Length Symmetry
Secondary study objectives
Free-living daily step count
Six-minute walk test
World Health Organization Disability Assessment Scale 2.0
Other study objectives
Socket Comfort Score
Transcutaneous oximetry
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Error-correction trainingExperimental Treatment1 Intervention
A 4-week, 8 session, treadmill-based gait training program, with error-correction of step asymmetry delivered with an auditory metronome signal while walking on a treadmill. During each training block, the metronome will be set to overcorrect stance time asymmetry through use of asymmetrical metronome tones, 2:1 ratio.
Group II: Error-augmentation trainingExperimental Treatment1 Intervention
A 4-week, 8 session, treadmill-based gait training program, with error-augmentation of step asymmetry delivered on a split-belt treadmill. Each training session will adhere to the same schedule. During the training blocks on the treadmill, the belt under the limb with the shorter step length will be set at 3/4 of the pre-intervention over-ground self-selected walking speed while the belt under the limb with the longer step length will be set to 1/2 of the fast belt speed (2:1 ratio between belts).
Group III: Supervised wakingActive Control1 Intervention
A 4-week, 8 session, treadmill-based supervised walking program. The active comparator group will participate in a supervised treadmill walking program of the same frequency and duration, to the two experimental groups.
Find a Location
Who is running the clinical trial?
VA Office of Research and DevelopmentLead Sponsor
1,663 Previous Clinical Trials
3,427,234 Total Patients Enrolled
Cory L. Christiansen, PhDPrincipal InvestigatorRocky Mountain Regional VA Medical Center, Aurora, CO
3 Previous Clinical Trials
223 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I do not have an unstable heart condition.I can walk on my own without any help from devices.I am currently receiving treatment for cancer.I currently have a serious infection.It has been 6 months to 10 years since my amputation.My walking step lengths are uneven.I had an amputation due to injury or cancer.I have diabetes and/or peripheral artery disease.I have had one lower leg amputated due to reasons other than injury.
Research Study Groups:
This trial has the following groups:- Group 1: Error-augmentation training
- Group 2: Supervised waking
- Group 3: Error-correction training
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger